SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sarepta Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$17.73+0.63 (+3.68%)
Close on Oct 19, 2026
- Market cap
- $1.87B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
108M of 106M shares
Institutional holders
323
49 new, 65 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $417.41K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| State Street Corporation | 8,916,103 | 8.40% | 13G (passive) | Jun 30, 2026 |
| Vanguard Portfolio Management | 8,499,421 | 8.05% | 13G (passive) amendment | Jun 30, 2026 |
| AQR Capital Management, LLC | 8,104,869 | 7.73% | 13G (passive) | Dec 31, 2025 |
| Vanguard Capital Management | 5,369,116 | 5.11% | 13G (passive) | Mar 31, 2026 |
| AQR Capital Management Holdings, LLC | 5,329,691 | 5.05% | 13G (passive) amendment | Jun 30, 2026 |
| David E. Shaw | 5,059,912 | 5.10% | 13G (passive) amendment | Jul 18, 2025 |
| BlackRock, Inc. | 16,642,620 | 15.80% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SRPT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 18,994,958 | 17.98% | $341.34M | +4,239,681 | 0.01% |
| State Street Corp | 8,916,090 | 8.44% | $160.22M | +2,302,776 | 0.00% |
| Vanguard Portfolio Management LLC | 8,377,470 | 7.93% | $150.54M | +1,736,778 | 0.01% |
| Two Sigma Investments, LP | 4,598,735 | 4.35% | $82.64M | +5,540 | 0.06% |
| Vanguard Capital Management LLC | 4,591,755 | 4.35% | $82.51M | +13,520 | 0.00% |
| First Trust Advisors LP | 4,365,951 | 4.13% | $78.46M | +230,163 | 0.05% |
| Aqr Capital Management LLC | 4,325,689 | 4.10% | $76.87M | −2,107,423 | 0.03% |
| Geode Capital Management, LLC | 2,771,758 | 2.62% | $49.82M | +782,962 | 0.00% |
| Erste Asset Management GmbH | 2,568,945 | 2.43% | $45.51M | −400,000 | 0.35% |
| Marshall Wace, Llp | 2,206,022 | 2.09% | $39.64M | +1,480,954 | 0.03% |
| Morgan Stanley | 2,202,641 | 2.09% | $39.58M | −394,352 | 0.00% |
| abrdn plc | 2,194,948 | 2.08% | $39.44M | −123,942 | 0.06% |
| Bank Of America Corp /De/ | 2,055,985 | 1.95% | $36.95M | −89,941 | 0.00% |
| Goldman Sachs Group Inc | 2,042,501 | 1.93% | $36.70M | +964,249 | 0.00% |
| UBS Group AG | 1,624,415 | 1.54% | $29.19M | −608,044 | 0.00% |
| Federated Hermes, Inc. | 1,590,331 | 1.51% | $28.58M | −195,690 | 0.04% |
| Northern Trust Corp | 1,210,732 | 1.15% | $21.76M | +486,473 | 0.00% |
| Millennium Management LLC | 1,193,468 | 1.13% | $21.45M | −28,214 | 0.01% |
| T. Rowe Price Investment Management, Inc. | 1,156,083 | 1.09% | $20.78K | +22,775 | 0.01% |
| Citigroup Inc | 1,155,006 | 1.09% | $20.76M | +7,358 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 323 | 108M | 100.0% | 49 / 98 | 118 / 65 | 22M | 17M |
| Q1 2026 | 344 | 103M | 97.4% | 50 / 109 | 130 / 48 | 31M | 10M |
| Q4 2025 | 348 | 94M | 88.9% | 74 / 137 | 90 / 42 | 20M | 14M |
| Q3 2025 | 320 | 87M | 82.8% | 65 / 109 | 105 / 106 | 26M | 22M |
| Q2 2025 | 363 | 83M | 78.9% | 64 / 160 | 89 / 128 | 31M | 34M |
| Q1 2025 | 430 | 87M | 82.2% | 71 / 147 | 148 / 101 | 11M | 11M |
| Q4 2024 | 465 | 88M | 83.3% | 78 / 158 | 157 / 64 | 10M | 10M |
| Q3 2024 | 458 | 89M | 84.4% | 58 / 171 | 158 / 82 | 21M | 12M |
| Q2 2024 | 485 | 91M | 86.0% | 120 / 178 | 131 / 45 | 15M | 11M |
| Q1 2024 | 415 | 87M | 82.3% | 77 / 144 | 123 / 55 | 10M | 8M |
| Q4 2023 | 396 | 85M | 80.2% | 75 / 123 | 140 / 66 | 15M | 14M |
| Q3 2023 | 395 | 84M | 79.1% | 50 / 155 | 125 / 55 | 12M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of SRPT | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 6,362,052 | 6.02% | $114.33M | 0.10% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 4,460,837 | 4.22% | $80.16M | 0.75% | Jun 30, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 3,583,400 | 3.39% | $64.39M | 2.29% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 3,187,072 | 3.02% | $57.27M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,697,422 | 2.55% | $48.47M | 0.06% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,297,038 | 2.17% | $41.28M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,332,977 | 1.26% | $23.95M | 0.05% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,204,690 | 1.14% | $21.65M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,137,988 | 1.08% | $16.91M | 0.05% | Jul 31, 2026 |
| Federated Hermes MDT Mid Cap Growth Fund | 1,106,479 | 1.05% | $16.44M | 0.25% | Jul 31, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 968,181 | 0.92% | $17.40M | 0.10% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 908,742 | 0.86% | $16.33M | 0.11% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 877,546 | 0.83% | $15.77M | 0.13% | Jun 30, 2026 |
| iShares Biotechnology ETF | 718,900 | 0.68% | $12.92M | 0.14% | Jun 30, 2026 |
| Vanguard Tax-Managed Small-Cap Fund | 699,514 | 0.66% | $12.57M | 0.11% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Severino | Chief Executive Officer, Director | 756,104 | 0.72% | Jul 29, 2026 |
| Douglas S. Ingram | Chief Executive Officer, Director | 659,849 | 0.62% | Dec 9, 2025 |
| Ian Michael Estepan | Chief Operating Officer | 177,184 | 0.17% | Sep 8, 2026 |
| Louise Rodino-Klapac | President, R&D and Tech Ops | 203,900 | 0.19% | Sep 8, 2026 |
| Cristin Rothfuss | EVP, General Counsel | 115,519 | 0.11% | Sep 8, 2026 |
| Ryan Ho-Yan Wong | Chief Financial Officer | 121,792 | 0.12% | Sep 8, 2026 |
| Bilal Arif | Chief Tech Ops Officer | 24,224 | 0.02% | Aug 6, 2025 |
| Dallan Murray | Chief Customer Officer | 29,926 | 0.03% | Mar 11, 2025 |
| M. Kathleen Behrens | Director | 224,357 | 0.21% | Jun 5, 2026 |
| Claude Nicaise | Director | 48,407 | 0.05% | Jun 5, 2026 |
| Deirdre P. Connelly | Director | 22,100 | 0.02% | Jun 5, 2026 |
| Richard Barry | Director | 3,233,542 | 3.06% | Jun 5, 2026 |
| Hans Lennart Rudolf Wigzell | Director | 42,098 | 0.04% | Jun 5, 2026 |
| Kathryn Jean Boor | Director | 25,138 | 0.02% | Jun 5, 2026 |
| Stephen Mayo | Director | 18,640 | 0.02% | Jun 5, 2026 |
| Michael Andrew Chambers | Director | 504,027 | 0.48% | Jun 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Louise Rodino-Klapac President, R&D and Tech Ops | Sep 4, 2026 | Tax withholding | −21,423 | $22.22 | $476.02K | 203,900 |
| Ian Michael Estepan Chief Operating Officer | Sep 4, 2026 | Tax withholding | −24,799 | $22.22 | $551.03K | 177,184 |
| Ryan Ho-Yan Wong Chief Financial Officer | Sep 4, 2026 | Tax withholding | −13,272 | $22.22 | $294.90K | 121,792 |
| Cristin Rothfuss EVP, General Counsel | Sep 4, 2026 | Tax withholding | −22,025 | $22.22 | $489.40K | 115,519 |
| Michael Severino Chief Executive Officer, Director | Jul 28, 2026 | Award | +756,104 | – | – | 756,104 |
| Richard Barry Director | Jun 4, 2026 | Award | +16,875 | – | – | 2,983,542 |
| Stephen Mayo Director | Jun 4, 2026 | Award | +16,875 | – | – | 18,640 |
| Michael Andrew Chambers Director | Jun 4, 2026 | Award | +16,875 | – | – | 27,535 |
| Hans Lennart Rudolf Wigzell Director | Jun 4, 2026 | Award | +16,875 | – | – | 42,098 |
| Deirdre P. Connelly Director | Jun 4, 2026 | Award | +16,875 | – | – | 22,100 |
| Kathryn Jean Boor Director | Jun 4, 2026 | Award | +16,875 | – | – | 25,138 |
| Claude Nicaise Director | Jun 4, 2026 | Award | +16,875 | – | – | 48,407 |
| M. Kathleen Behrens Director | Jun 4, 2026 | Award | +16,875 | – | – | 214,357 |
| Stephen Mayo Director | Mar 12, 2026 | Sale | −7,239 | $17.02 | $123.21K | 1,765 |
| Cristin Rothfuss EVP, General Counsel | Mar 11, 2026 | Tax withholding | −974 | $17.03 | $16.59K | 137,544 |
| Ryan Ho-Yan Wong Chief Financial Officer | Mar 11, 2026 | Tax withholding | −256 | $17.03 | $4.36K | 135,064 |
| Ian Michael Estepan Chief Operating Officer | Mar 11, 2026 | Tax withholding | −1,097 | $17.03 | $18.68K | 201,983 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 11, 2026 | Tax withholding | −948 | $17.03 | $16.14K | 225,323 |
| Ryan Ho-Yan Wong Chief Financial Officer | Mar 9, 2026 | Tax withholding | −162 | $16.95 | $2.75K | 135,433 |
| Ryan Ho-Yan Wong Chief Financial Officer | Mar 9, 2026 | Tax withholding | −113 | $16.95 | $1.92K | 135,320 |
| Cristin Rothfuss EVP, General Counsel | Mar 9, 2026 | Tax withholding | −484 | $16.95 | $8.20K | 138,864 |
| Cristin Rothfuss EVP, General Counsel | Mar 9, 2026 | Tax withholding | −346 | $16.95 | $5.86K | 138,518 |
| Ian Michael Estepan Chief Operating Officer | Mar 9, 2026 | Tax withholding | −583 | $16.95 | $9.88K | 203,080 |
| Ian Michael Estepan Chief Operating Officer | Mar 9, 2026 | Tax withholding | −1,036 | $16.95 | $17.56K | 203,663 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 9, 2026 | Tax withholding | −504 | $16.95 | $8.54K | 227,166 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 9, 2026 | Tax withholding | −895 | $16.95 | $15.17K | 226,271 |
| Cristin Rothfuss EVP, General Counsel | Mar 2, 2026 | Tax withholding | −408 | $16.20 | $6.61K | 139,348 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 2, 2026 | Tax withholding | −3,718 | $16.20 | $60.23K | 228,437 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 2, 2026 | Tax withholding | −767 | $16.20 | $12.43K | 227,670 |
| Ryan Ho-Yan Wong Chief Financial Officer | Mar 2, 2026 | Tax withholding | −450 | $16.20 | $7.29K | 135,595 |
| Ian Michael Estepan Chief Operating Officer | Mar 2, 2026 | Tax withholding | −3,301 | $16.20 | $53.48K | 205,574 |
| Ian Michael Estepan Chief Operating Officer | Mar 2, 2026 | Tax withholding | −875 | $16.20 | $14.18K | 204,699 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Mar 1, 2026 | Option exercise | +8,125 | – | – | 232,155 |
| Ian Michael Estepan Chief Operating Officer | Mar 1, 2026 | Option exercise | +8,125 | – | – | 208,875 |
| Ian Michael Estepan Chief Operating Officer | Feb 26, 2026 | Option exercise | +5,381 | $13.71 | $73.77K | 200,750 |
| Ian Michael Estepan Chief Operating Officer | Feb 26, 2026 | Option exercise | +2,069 | $13.71 | $28.37K | 195,369 |
| Claude Nicaise Director | Jan 29, 2026 | Option exercise | +10,500 | $13.71 | $143.96K | 38,312 |
| Claude Nicaise Director | Jan 29, 2026 | Tax withholding | −6,780 | $21.23 | $143.94K | 31,532 |
| M. Kathleen Behrens Director | Jan 27, 2026 | Tax withholding | −6,494 | $22.17 | $143.97K | 197,482 |
| M. Kathleen Behrens Director | Jan 27, 2026 | Option exercise | +10,500 | $13.71 | $143.96K | 203,976 |
| Ian Michael Estepan Chief Operating Officer | Dec 16, 2025 | Sale | −13,187 | $22.31 | $294.20K | 193,300 |
| Douglas S. Ingram Chief Executive Officer, Director | Dec 7, 2025 | Award | +96,541 | – | – | 659,849 |
| Douglas S. Ingram Chief Executive Officer, Director | Dec 7, 2025 | Award | +269,542 | – | – | 929,391 |
| Douglas S. Ingram Chief Executive Officer, Director | Dec 7, 2025 | Award | +50,000 | – | – | 440,307 |
| Douglas S. Ingram Chief Executive Officer, Director | Dec 7, 2025 | Award | +50,000 | – | – | 490,307 |
| Douglas S. Ingram Chief Executive Officer, Director | Dec 7, 2025 | Award | +73,001 | – | – | 563,308 |
| Ryan Ho-Yan Wong Chief Financial Officer | Dec 1, 2025 | Tax withholding | −78 | $20.96 | $1.63K | 136,045 |
| Ryan Ho-Yan Wong Chief Financial Officer | Dec 1, 2025 | Tax withholding | −80 | $20.96 | $1.68K | 136,123 |
| Cristin Rothfuss EVP, General Counsel | Nov 28, 2025 | Tax withholding | −229 | $21.12 | $4.84K | 139,756 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Nov 17, 2025 | Tax withholding | −4,582 | $18.42 | $84.40K | 224,030 |
| Cristin Rothfuss EVP, General Counsel | Sep 3, 2025 | Award | +93,875 | – | – | 114,985 |
| Cristin Rothfuss EVP, General Counsel | Sep 3, 2025 | Award | +25,000 | – | – | 139,985 |
| Ryan Ho-Yan Wong Chief Financial Officer | Sep 3, 2025 | Award | +93,875 | – | – | 111,203 |
| Ryan Ho-Yan Wong Chief Financial Officer | Sep 3, 2025 | Award | +25,000 | – | – | 136,203 |
| Ian Michael Estepan Chief Operating Officer | Sep 3, 2025 | Award | +93,875 | – | – | 156,487 |
| Ian Michael Estepan Chief Operating Officer | Sep 3, 2025 | Award | +50,000 | – | – | 206,487 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Sep 3, 2025 | Award | +50,000 | – | – | 228,612 |
| Louise Rodino-Klapac President, R&D and Tech Ops | Sep 3, 2025 | Award | +93,875 | – | – | 178,612 |
| Ryan Ho-Yan Wong Chief Financial Officer | Jul 31, 2025 | Tax withholding | −327 | $16.42 | $5.37K | 17,328 |
| Richard Barry Director | May 16, 2025 | Option exercise | +12,350 | $32.63 | $402.98K | 2,966,667 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mayo Stephen Director | Mar 12, 2026 | 7,239 | $123.18K | Mar 12, 2026 | Restricted Stock |
| M. Estepan Ian Officer | Dec 16, 2025 | 13,187 | $294.15K | Dec 16, 2025 | Exercised Shares |
| Sarepta Therapeutics, Inc. Shareholder | Aug 13, 2025 | 9,265,312 | $185.21M | Aug 13, 2025 | The common stock reported herein was acquired by Sarepta Therapeutics Investments, Inc., a wholly owned subsidiary of Sarepta Therapeutics, Inc., in a private placement transaction. |
| Claude Nicaise Director | Mar 12, 2025 | 2,491 | $248.23K | Mar 12, 2025 | STOCK OPTION EXERCISE |
| Hans Lennart Rudolf Wigzell Director | Dec 12, 2024 | 10,500 | $1.31M | Dec 12, 2024 | STOCK OPTION EXERCISE |
| Kathryn Jean Boor Director | Dec 5, 2024 | 1,636 | $205.40K | Dec 5, 2024 | RESTRICTED STOCK |
| Ian Michael Estepan Officer | Aug 30, 2024 | 5,985 | $822.13K | Aug 30, 2024 | RESTRICTED STOCK |
| Arif Bilal Officer | Jun 25, 2024 | 3,898 | $638.69K | Jun 25, 2024 | Performance Stock Units |
| Brown Ryan Officer | Jun 25, 2024 | 38,957 | $6.38M | Jun 25, 2024 | Restricted Stock Units |
| Arif Bilal Officer | Jun 24, 2024 | 7,859 | $1.26M | Jun 24, 2024 | Employee Stock Purchase Plan |
| Kathryn Jean Boor Director | Mar 11, 2024 | 761 | $93.55K | Mar 11, 2024 | RESTRICTED STOCK |
| Hans Lennart Rudolf Wigzell Director | Mar 8, 2024 | 15,000 | $1.93M | Mar 8, 2024 | STOCK OPTION EXERCISE |
| Stephen Mayo Director | Mar 5, 2024 | 3,135 | $385.48K | Mar 5, 2024 | RESTRICTED STOCK |
| Ian Michael Estepan Officer | Mar 1, 2024 | 1,565 | $200.02K | Mar 1, 2024 | RESTRICTED STOCK |
| Arif Bilal Officer | Mar 1, 2024 | 2,000 | $257.67K | Mar 1, 2024 | Employee stock unit award(s) |